4XXS image
Entry Detail
PDB ID:
4XXS
Title:
Crystal structure of BACE1 with a pyrazole-substituted tetrahydropyran thioamidine
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2015-01-30
Release Date:
2015-04-01
Method Details:
Experimental Method:
Resolution:
1.86 Å
R-Value Free:
0.20
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 61 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Beta-secretase 1
Chain IDs:A
Chain Length:415
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors.
J.Med.Chem. 58 3223 3252 (2015)
PMID: 25781223 DOI: 10.1021/acs.jmedchem.5b00191

Abstact

In recent years, the first generation of β-secretase (BACE1) inhibitors advanced into clinical development for the treatment of Alzheimer's disease (AD). However, the alignment of drug-like properties and selectivity remains a major challenge. Herein, we describe the discovery of a novel class of potent, low clearance, CNS penetrant BACE1 inhibitors represented by thioamidine 5. Further profiling suggested that a high fraction of the metabolism (>95%) was due to CYP2D6, increasing the potential risk for victim-based drug-drug interactions (DDI) and variable exposure in the clinic due to the polymorphic nature of this enzyme. To guide future design, we solved crystal structures of CYP2D6 complexes with substrate 5 and its corresponding metabolic product pyrazole 6, which provided insight into the binding mode and movements between substrate/inhibitor complexes. Guided by the BACE1 and CYP2D6 crystal structures, we designed and synthesized analogues with reduced risk for DDI, central efficacy, and improved hERG therapeutic margins.

Legend

Protein

Chemical

Disease

Primary Citation of related structures